Halozyme Therapeutics, Inc. vs. Surrozen, Inc. Common
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| HALO | SRZN | |
|---|---|---|
| Market Cap | $12.76 billion | $189.94 million |
| Revenue (TTM) | $1.66 billion | $11.51 million |
| Net Income (TTM) | $413.60 million | $-332,130,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | SRZN | |
|---|---|---|
| P/E Ratio | 33.59 | — |
| Price / Book | 88.91 | -0.87 |
| Price / Sales | 7.67 | 16.50 |
HALO and SRZN split the valuation factors evenly.
Profitability
| HALO | SRZN | |
|---|---|---|
| Net Margin | 24.86% | -2885.33% |
| Return on Equity | 288.13% | 151.89% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | SRZN | |
|---|---|---|
| Short Interest | 9.79% | 0.33% |
SRZN leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, SRZN overview, SRZN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.